InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
1
T+90 hit rate
100%
T+90 mean return
+39.2%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Lichter Jay, Director. Insider active across 1 company, notably Janux Therapeutics, Inc.. In total, 6 filings have been recorded. Breakdown: 1 buy · 1 sell. Total volume traded: €38.7m. History available since 13 November 2023. The latest transaction was filed on 13 September 2024 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations6 total
1,868 shares@ US$17.000.1% of flowCommon StockSEC:0001415889-24-025601:0
2,500 shares0Common StockSEC:0001415889-24-018443:0
677,279 shares@ US$54.7587.9% of flowCommon StockSEC:0001415889-24-015678:0
849,854 shares@ US$5.8712.1% of flowCommon StockSEC:0001209191-23-055349:0
Canonical exit: 11 Feb 2024 (T+90)
1,138,665 sharesCommon StockSEC:0001209191-21-041038:0
1,138,665 sharesCommon StockSEC:0001209191-21-041038
6 of 6 declarations
About Lichter Jay
Jay Lichter is a Director at Janux Therapeutics, Inc., a biotechnology company specializing in the development of targeted therapies. As a director, he participates in the governance of the company and contributes his expertise in the biotechnology field. His role is crucial in guiding the strategic decisions of Janux Therapeutics, Inc.
